Rho-Kinase Inhibitors For The Treatment Of Glaucoma

Drug manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral part of cellular functions such as contraction of...

Drug manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral part of cellular functions such as contraction of vascular smooth muscle cells, organization of the actin cytoskeleton, cell adhesion and motility and gene expression. These inhibitors are different from widely used prostaglandin analogs because they target the outflow through trabecular meshwork rather than the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours, which is more effective than the previous generation of drugs for this condition. Major Rho-kinase inhibitors being developed include ATS907, ATS8535, AR-12286, AR-13324, AMA0076 and BOL-303259-X.

 

THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL OPHTHALMOLOGY DRUGS MARKET TO GROW TO $38 BILLION BY 2021

 

North America was the largest region in the ophthalmology drugs market in 2017, accounting for one-third of the market share. This was mainly due to the high per capita healthcare expenditure and access to advanced eye care facilities in the region.

 

Order the report at https://www.thebusinessresearchcompany.com/report/ophthalmology-drugs-global-market-report-2018

 

The chart below shows the year-on-year growth of global ophthalmology drugs market during 2017 – 2021

 

According to The Business Research Company’s Consultant, Nitin Gianchandani, drug manufacturers are increasingly developing ophthalmic drugs with anti-inflammatory agents to ease patient treatment for dry eye syndrome. Anti-inflammatory drugs are widely used for the treatment of the inflammation produced by the disease with the topical corticosteroid drops being the most common therapy. Corticosteroids can rapidly and effectively relieve the symptoms and signs of moderate or severe dry eye. However, prolonged usage of corticosteroids has seen to produce side effects that include risk of bacterial or fungal infection, elevated intraocular pressure and cataract formation. As a consequence, NSAIDs are increasingly being used as dry eye treatment instead of steroids because of their non-severe side effects. For instance, Aciex Therapeutics, a US-based pharmaceutical company, is developing NSAIDs which decrease ocular discomfort.

 

Download a sample of the report at:

https://www.thebusinessresearchcompany.com/sample.aspx?id=281&type=smp

 

Novartis AG was the largest competitor in the ophthalmology drugs market, with revenues of $6.3 billion for the financial year 2016. Novartis’ growth strategy is to focus on strengthening its ophthalmology pipeline through acquisitions. In December 2016, the company acquired pharmaceutical company Encore Vision, Inc. that develops treatment for presbyopia, an ophthalmologic disorder. In addition, Novartis is focusing on licensing new products to enhance its ophthalmology pipeline. For instance, in April 2017, it entered into a deal with Boston-based biopharma company, Lubris LLC., to in-license its ECF843 compound that is been developed for the treatment of dry eye syndrome (DES).

 

The ophthalmology drugs market covers drugs that are used in the treatment of eye related diseases such as refractive errors, cataracts, glaucoma, conjunctivitis, retinal diseases, and macular degeneration. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax. The market numbers in this briefing cover pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

 

Ophthalmology Drugs Global Market Report 2018 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office, the price is $6000 and $8000 if you wish to use across a multinational company.

 

About The Business Research Company:

 

Visit TheBusinessResearchCompany.com, mail [email protected] or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.

 

The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.

 

It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.

 

The Business Research Company’s management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations.

 

Contact Information:

 

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: [email protected]

 

Categories
Health And Fitness
No Comment

Leave a Reply

*

*